Some physicians prescribe low-molecular-weight heparin (LMWH) for pregnant women with a history of unexplained recurrent pregnancy loss (RPL). Past studies show that LMWH may increase the live-birth rate for pregnant women who have thrombophilic disorders, which increase the risk for excessive clotting. Many women with unexplained RPL probably do not have thrombophilic disorders, however, so whether LMWH could improve outcomes for these women is unclear.
ETHIG II group.

What is the problem and what is known about it so far?
Some physicians prescribe low-molecular-weight heparin (LMWH) for pregnant women with a history of unexplained recurrent pregnancy loss (RPL) . Past studies show that LMWH may increase the live-birth rate for pregnant women who have thrombophilic disorders, which increase the risk for excessive clotting. Many women with unexplained RPL probably do not have thrombophilic disorders, however, so whether LMWH could improve outcomes for these women is unclear.
Why did the researchers do this particular study? To find out whether LMWH increases ongoing pregnancy and live-birth rates in pregnant women with a history of unexplained RPL.
Who was studied? 449 pregnant women who had a history of miscarriages.
How was the study done?
Participants were recruited from 14 outpatient clinics that specialized in unexplained pregnancy loss. Potential participants were tested for thrombophilic disorders and were excluded if they had major disorders. Eligible women at 5 to 8 weeks' gestation were randomly assigned to receive daily multivitamin pills or vitamin pills plus LMWH (5000 IU of dalteparin-sodium) injections. Women self-administered the injections daily until at least 24 weeks' gestation. Women not assigned to LMWH were not given placebo injections. The primary outcome was the ongoing pregnancy rate up to and including the 24th week of gestation.
What did the researchers find?
About 86% to 87% of women in both groups had intact pregnancies at 24 weeks' gestation and had live births. Women tolerated the injections well; none discontinued injections because of side effects.
What were the limitations of the study? Participants and their providers were aware of which intervention patients received.
What are the implications of the study? Low-molecular-weight heparin does not increase ongoing pregnancy or live-birth rates in women with unexplained RPL. 
